Fuchs E F, Horton D, Weckerle W, Winter B
J Antibiot (Tokyo). 1979 Mar;32(3):223-38. doi: 10.7164/antibiotics.32.223.
Glycosidation of 2,3,6-trideoxy-3-trifluoroacetamido-4-O-trifluoroacetyl-alpha-D-arabino-hexopyranosyl chloride (19) (or the corresponding 4-p-nitrobenzoate, 20) with daunomycinone under Koenigs-Knorr conditions afforded, after separation of the anomers and removal of the protecting groups, the individual target glycosides 8 (alpha anomer; major product) and 9 (beta; minor) in acceptable yields. In contrast, the title diamino sugar, suitably protected with N-trifluoroacetyl and O-acetyl (or O-p-nitrobenzoyl) groups, underwent stereospecific coupling to the anthracycline aglycon by the glycal procedure to give, after deprotection, the alpha glycoside 12. All three analogs were assayed in vivo against P388 lymphocytic leukemia. They showed little (T/C 125 for 8; T/C 115 for 9) or no (compound 12) activity, but were essentially devoid of toxicity at the dose-levels tested.
在柯尼希斯-克诺尔条件下,使2,3,6-三脱氧-3-三氟乙酰氨基-4-O-三氟乙酰基-α-D-阿拉伯己糖基氯(19)(或相应的4-对硝基苯甲酸酯,20)与柔红霉素酮进行糖苷化反应,在分离端基异构体并除去保护基后,以可接受的产率得到了各个目标糖苷8(α端基异构体;主要产物)和9(β;次要产物)。相比之下,用N-三氟乙酰基和O-乙酰基(或O-对硝基苯甲酰基)进行适当保护的标题二氨基糖,通过糖烯方法与蒽环类苷元进行立体定向偶联,脱保护后得到α糖苷12。对所有三种类似物进行了抗P388淋巴细胞白血病的体内试验。它们显示出很少的活性(8的T/C为125;9的T/C为115)或没有活性(化合物12),但在测试的剂量水平下基本没有毒性。